News
EDSA
2.130
-1.84%
-0.040
Weekly Report: what happened at EDSA last week (1026-1030)?
Weekly Report · 3d ago
Edesa Biotech’s EB05 COVID-19 Trial Terminated: What Investors Should Know
TipRanks · 10/28 16:30
Edesa Biotech Advances EB06 Vitiligo Trial, Keeping Investor Focus on Phase 2 Progress
TipRanks · 10/27 16:30
Weekly Report: what happened at EDSA last week (1019-1023)?
Weekly Report · 10/26 09:09
Edesa Biotech Boosts Executive Compensation and Equity Alignment
TipRanks · 10/23 21:49
12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga · 10/20 21:05
Weekly Report: what happened at EDSA last week (1012-1016)?
Weekly Report · 10/19 09:09
Edesa Secures FDA Clearance To Expand Phase 2 Vitiligo Trial Of EB06 Into U.S
NASDAQ · 10/15 14:13
Edesa Biotech advances EB06 vitiligo Phase 2 trial
TipRanks · 10/15 13:50
Edesa Biotech announces FDA clearance for vitiligo study
TipRanks · 10/15 13:36
Edesa Biotech Receives FDA Clearance For Its Investigational New Drug Application For Its Phase 2 Clinical Trial Of EB06 In Vitiligo
Benzinga · 10/15 13:16
Weekly Report: what happened at EDSA last week (1005-1009)?
Weekly Report · 10/12 09:10
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/08 21:05
Weekly Report: what happened at EDSA last week (0928-1002)?
Weekly Report · 10/05 09:10
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga · 10/01 21:06
Weekly Report: what happened at EDSA last week (0921-0925)?
Weekly Report · 09/28 09:09
Weekly Report: what happened at EDSA last week (0914-0918)?
Weekly Report · 09/21 09:09
Weekly Report: what happened at EDSA last week (0907-0911)?
Weekly Report · 09/14 09:09
Weekly Report: what happened at EDSA last week (0831-0904)?
Weekly Report · 09/07 09:09
Weekly Report: what happened at EDSA last week (0824-0828)?
Weekly Report · 08/31 09:10
More
Webull provides a variety of real-time EDSA stock news. You can receive the latest news about Edesa Biotech Inc through multiple platforms. This information may help you make smarter investment decisions.
About EDSA
Edesa Biotech, Inc. is a clinical-stage biopharmaceutical company developing ways to treat inflammatory and immune-related diseases. The Company’s clinical pipeline is focused on two therapeutic areas: medical dermatology and respiratory. In medical dermatology, the Company is developing EB06, an anti-CXCL10 monoclonal antibody candidate, as a therapy for vitiligo, a common autoimmune disorder that causes skin to lose its color in patches. Its medical dermatology assets also include EB01 (1.0% daniluromer cream), a Phase III-ready asset developed for use as a potential therapy for moderate-to-severe chronic allergic contact dermatitis (ACD), a common occupational skin condition. The Company’s advanced respiratory drug candidate is EB05 (paridiprubart), which is being evaluated in a United States government-funded platform study as a treatment for acute respiratory distress syndrome.